Carefusion Corporation (CFN) January 09, 2012 9:00 am ET Executives Kieran T. Gallahue - Chairman and Chief Executive Officer James F. Hinrichs - Chief Financial Officer Jim Mazzola - Senior Vice President of Global Marketing and Communication Analysts Lennox Ketner - BofA Merrill Lynch, Research Division Michael N. Weinstein - JP Morgan Chase & Co, Research Division Amit Bhalla - Citigroup Inc, Research Division David H. Roman - Goldman Sachs Group Inc., Research Division Matthew Taylor - Barclays Capital, Research Division Kristen M. Stewart - Deutsche Bank AG, Research Division David R. Lewis - Morgan Stanley, Research Division PresentationOperator
Good day, ladies and gentlemen, and welcome to the CareFusion Corporation Investor Meeting. My name is Pamela, and I'll be your operator for today. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. At this time, I would like to turn the conference over to Mr. Jim Mazzola. Please proceed. Jim Mazzola Thank you, Pamela. This is Jim Mazzola, and thanks for joining us on today's call as we discuss CareFusion's preliminary results for the second fiscal quarter ended December 31, 2011, and provide updated guidance for our fiscal 2012. We issued a news release containing our preliminary financial results this morning at 8:00 a.m. Eastern time, which is posted in our website at carefusion.com and filed on Form 8-K with the SEC. Joining me on today's call are Kieran Gallahue, our Chairman and CEO; and Jim Hinrichs, our CFO. Before I turn the call over to Kieran, I would like to make a few remarks. In today's call, we will discuss some non-GAAP financial measures, including financial results on an adjusted basis. A reconciliation to GAAP measures can be found in today's release and on the Investors section of our website. We believe these adjusted financial measures can facilitate a more complete analysis and greater transparency into CareFusion's ongoing results of operations, particularly in comparing underlying results from period to period.